A5018267315- Multiple Sclerosis Research Studies
- Alzheimer's disease research and treatments
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Meningioma and schwannoma management
- Cancer Immunotherapy and Biomarkers
- Mycobacterium research and diagnosis
- Ophthalmology and Eye Disorders
- Retinal and Macular Surgery
- Functional Brain Connectivity Studies
- IgG4-Related and Inflammatory Diseases
- Digital Economy and Work Transformation
- Parasites and Host Interactions
- Immunotherapy and Immune Responses
- Pituitary Gland Disorders and Treatments
- Mosquito-borne diseases and control
- Mitochondrial Function and Pathology
- Monoclonal and Polyclonal Antibodies Research
- Retinal Development and Disorders
- Trypanosoma species research and implications
- Glaucoma and retinal disorders
- Plant Virus Research Studies
- Rheumatoid Arthritis Research and Therapies
University of Colorado Denver
2015-2024
Rocky Mountain MS Center
2022-2024
Johns Hopkins Medicine
2024
Brigham and Women's Hospital
2024
Johns Hopkins University
2024
University of Colorado System
2024
University of Colorado Anschutz Medical Campus
2013-2023
National Institutes of Health
2022
Centre de droit comparé du travail et de la sécurité sociale
2022
National Multiple Sclerosis Society
2022
Object Despite improvements in the medical and surgical management of patients with glioblastoma, tumor recurrence remains inevitable. For recurrent however, clinical value a second resection uncertain. Specifically, what proportion contrast-enhancing glioblastoma tissue must be removed to improve overall survival is neurological cost incremental beyond this threshold? Methods The authors identified 170 consecutive supratentorial glioblastomas treated at Barrow Neurological Institute from...
In vivo PET imaging studies of young-adult carriers the apolipoprotein E ε4 allele (APOEε4), major Alzheimer's disease (AD) susceptibility gene, have demonstrated declines in glucose metabolism brain areas later vulnerable to AD, such as po
Patients with atypical meningioma often undergo gross-total resection (GTR) at initial presentation, but the role of adjuvant radiation therapy remains unclear. The increasing prevalence stereotactic radiosurgery (SRS) in modern neurosurgical era has led to use routine postoperative absence evidence-based guidelines. This study sought define long-term recurrence rate meningiomas and identify value SRS affecting outcome.The authors identified 228 patients microsurgically treated who underwent...
Recent evidence suggests that a greater extent of resection (EOR) extends malignant progression-free survival among patients with low-grade gliomas (LGGs). These studies, however, rely on the combined analysis oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas-3 histological subtypes distinct genetic molecular compositions. To assess value EOR in homogeneous LGG patient population delineate its impact transformation, authors examined effect newly diagnosed supratentorial...
The APOE gene, encoding apolipoprotein E, is the primary genetic risk factor for late-onset Alzheimer's disease (AD).Apolipoprotein E 4 allele (APOE4) carriers have alterations in brain structure and function (as measured by imaging) even as young adults.Examination of this population valuable further identifying details these functional changes their association with vulnerability to AD decades later.Previous work demonstrates declines mitochondrial activity posterior cingulate cortex, a...
Strategies for sequencing disease modifying therapies (DMTs) in multiple sclerosis (MS) patients include escalation, high efficacy early, induction, and de-escalation.To provide a perspective on de-escalation, which aims to match the ratio of DMT benefit/risk aging patients.We reanalyzed data from retrospective, real-world cohort MS model activity oral (dimethyl fumarate fingolimod) higher infusible (natalizumab rituximab) DMTs by age. For with relapsing MS, we conducted controlled,...
Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients certain preexisting autoimmune diseases, and these also experience exacerbation the underlying disease following ICI initiation. People multiple sclerosis (MS) have mostly been excluded from clinical trials ICIs, so data on safety ICIs MS limited. This study aims to assess rate activity, as well neurologic...
Disease-modifying therapy (DMT) for multiple sclerosis (MS) after natalizumab-associated progressive multifocal leukoencephalopathy (PML) is controversial due to concern recurrent PML. We describe DMT utilization over a decade in patient with MS who survived
The COVID-19 pandemic has resulted in challenges for the practice of neurology. One major concern is how to best manage patients with multiple sclerosis (MS) who are on disease-modifying therapies (DMTs). DMTs frequently have immunosuppressive properties that both increase risk and potentially reduce immunologic response vaccination a group already vulnerable infection due neurologic deficits. Here, we review early data outcomes MS discuss what known about vaccine effectiveness those...
To define multiple sclerosis (MS) disease activity and neurologic outcomes after exposure to immune checkpoint inhibitors (ICIs) as cancer therapy.
Nutrition has been highlighted as a potential factor in Alzheimer's disease (AD) risk and decline investigated therapeutic target. Broad-based combination diet therapies have the to simultaneously effect numerous protective corrective processes, both directly (e.g., neuroprotection) indirectly improved vascular health). Here we administered either normal mouse chow with broad-based nutritional supplement or alone aged male female 3xTg mice wildtype (WT) controls. After approximately 4 months...
To report a case of JC virus granule cell neuronopathy (GCN) mimicking paraneoplastic cerebellar degeneration (PCD).